<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Emicizumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Emicizumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Emicizumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="115772" href="/d/html/115772.html" rel="external">see "Emicizumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="115859" href="/d/html/115859.html" rel="external">see "Emicizumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F50787366"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Thrombotic microangiopathy and thromboembolism:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of &gt;100 units/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving emicizumab prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of emicizumab if symptoms occur.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50812749"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Hemlibra</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872332"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Hemlibra</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F51309995"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block don drugH1Div" id="F53462703"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b6ec261-7f84-46c6-93e5-cae09f1044f2">Hemophilia A, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A, prophylaxis: Note:</b> Prophylactic use of bypassing agents should be discontinued the day before starting therapy. Prophylactic use of FVIII may be continued during the first week of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial loading dose: SubQ: 3 mg/kg once weekly for first 4 weeks (4 doses)</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance therapy: <b>Note:</b> Multiple regimens available, and selection should be based on health care provider preferences and increased patient adherence. SubQ: 1.5 mg/kg once weekly <b>or</b> 3 mg/kg once every 2 weeks <b>or</b> 6 mg/kg once every 4 weeks</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F50848425"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b6ec261-7f84-46c6-93e5-cae09f1044f2">Hemophilia A, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A, prophylaxis: Note:</b> Prophylactic use of bypassing agents should be discontinued the day before starting therapy. Prophylactic use of FVIII may be continued during the first week of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial loading dose: SubQ: 3 mg/kg once weekly for first 4 weeks (4 doses)</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance therapy: <b>Note:</b> Multiple regimens available, and selection should be based on health care provider preferences and increased patient adherence. SubQ: 1.5 mg/kg once weekly <b>or</b> 3 mg/kg once every 2 weeks <b>or</b> 6 mg/kg once every 4 weeks</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51126761"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; the pharmacokinetics of emicizumab were not shown to be altered in patients with mild (CrCl 60 to 89 mL/minute) and moderate (CrCl 30 to 59 mL/minute) renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51126770"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; the pharmacokinetics of emicizumab were not shown to be altered in patients with mild (total bilirubin 1 to 1.5 times ULN) and moderate (total bilirubin 1.5 to 3 times ULN) hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F50848424"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="115772" href="/d/html/115772.html" rel="external">see "Emicizumab: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b6ec261-7f84-46c6-93e5-cae09f1044f2">Hemophilia A, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A, prophylaxis:</b>
<b>SUBQ</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 3 mg/kg once weekly for 4 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: 1.5 mg/kg once weekly <i>
<b>or </b></i>3 mg/kg once every 2 weeks <b>
<i>or</i></b> 6 mg/kg once every 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Prophylactic use of bypassing agents should be discontinued the day before starting therapy. Prophylactic use of FVIII may be continued during the first week of therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991543"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988652"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F50795133"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in pediatric patients and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (22%, including bruising at injection site, discomfort at injection site, erythema at injection site [11%], hematoma at injection site, induration at injection site, injection-site pruritus [4%], pain at injection site [4%], rash at injection site, swelling at injection site, urticaria at injection site, warm sensation at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (5%; neutralizing: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Neuromuscular &amp; skeletal: Rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Superficial thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombotic microangiopathy</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p></div>
<div class="block coi drugH1Div" id="F50787368"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Hypersensitivity to emicizumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F50848414"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Antibody formation may occur but is rarely associated with a decrease in emicizumab plasma concentrations or a decrease in efficacy. If clinical signs of loss of efficacy (eg, increase in breakthrough bleeding events) occur, consider a change in therapy if neutralizing anti-emicizumab antibodies are suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic microangiopathy and thromboembolism: Patients presented with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, without severe deficiencies in ADAMTS13 activity; improvement of thrombotic microangiopathy and thromboembolism was seen within 1 week and 1 month, respectively, following discontinuation of activated prothrombin complex concentrate (aPCC). The potential for an interaction with aPCC may persist for up to 6 months after the last dose of emicizumab due to the long half-life of emicizumab. If these complications occur, discontinue aPCC immediately and interrupt emicizumab; consider benefits vs risks of resuming emicizumab following complete resolution of thrombotic microangiopathy and thrombotic events.</p></div>
<div class="block foc drugH1Div" id="F50812750"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemlibra: Emicizumab-kxwh 300 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemlibra: Emicizumab-kxwh 30 mg/1 mL (1 mL); Emicizumab-kxwh 150 mg/1 mL (1 mL); Emicizumab-kxwh 60 mg/0.4 mL (0.4 mL); Emicizumab-kxwh 105 mg/0.7 mL (0.7 mL)</p></div>
<div class="block geq drugH1Div" id="F50812748"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51083819"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hemlibra Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/mL (per mL): $4,030.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg/0.4 mL (per 0.4 mL): $8,060.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg/0.7 mL (per 0.7 mL): $14,105.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $20,150.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/2 mL (per mL): $20,150.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872333"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemlibra: Emicizumab-kxwh 30 mg/1 mL (1 mL); Emicizumab-kxwh 150 mg/1 mL (1 mL); Emicizumab-kxwh 60 mg/0.4 mL (0.4 mL); Emicizumab-kxwh 105 mg/0.7 mL (0.7 mL)</p></div>
<div class="block admp drugH1Div" id="F52614669"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">SubQ: For SubQ administration. Do not shake. Administer immediately after removal of dose from vial. Use an 18-gauge transfer needle containing a 5-micron filter to withdraw dose and a 26-gauge injection needle (acceptable range: 25 to 27 gauge) with a <sup>3</sup>/<sub>8</sub>- to <sup>1</sup>/<sub>2</sub>-inch needle to administer dose. Administer doses up to 1 mL with a 1 mL syringe and doses &gt;1 mL and up to 2 mL with a 2 or 3 mL syringe. Rotate injection sites (upper outer arms, thighs, or any quadrant of abdomen). Do not inject into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Patient may self-inject or the patient's caregiver may administer after training; however, only a health care provider or caregiver should administer in the upper outer arm. Self-administration is not recommended for patients &lt;7 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to product information for preparation and additional administration techniques. Do not use different vials of different concentrations when combining vials to administer prescribed dose.</p></div>
<div class="block adm drugH1Div" id="F50848436"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> For SUBQ administration. Do not shake. Use an 18-gauge transfer needle containing a 5-micron filter to withdraw dose and a 26-gauge injection needle (acceptable range: 25 to 27 gauge) with a 3/8- to ½-inch needle to administer dose. Administer immediately after removal from vial. Administer doses up to 1 mL with a 1 mL syringe and doses &gt;1 mL and up to 2 mL with a 2 or 3 mL syringe. Rotate injection sites (upper outer arms, thighs, or any quadrant of abdomen). Do not inject into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact. Patient may self-inject, or the patient's caregiver may administer; however, only a health care provider should administer in the upper outer arm. Self-administration is not recommended for children &lt;7 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to product information for preparation and additional administration techniques. Do not use different vials of different concentrations when combining vials to administer prescribed dose.</p></div>
<div class="block sts drugH1Div" id="F50848417"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F); protect from light. Do not freeze. May also store unopened vials at &lt;30°C (&lt;86°F) for up to 7 days. Once removed from the vial, discard if not used immediately. Discard unused solution.</p></div>
<div class="block meg drugH1Div" id="F56206745"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Hemlibra: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F761083s011lbl.pdf%23page%3D21&amp;token=CKciBN1SiHGAB1QXOYWYd%2BUcmYooopLAgySxjKSn2B4Hb46eSqbOQdYEbTtyfjyCnNKAvsKav8K%2FEZtKy%2Bth7TL1igDrhUOZ6TTk5d1XNkFAoi%2FjeW6A5357NGjWWE07&amp;TOPIC_ID=119618" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761083s011lbl.pdf#page=21</a></p></div>
<div class="block usep drugH1Div" id="F53571440"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors (FDA approved in all ages)</p></div>
<div class="block cyt drugH1Div" id="F50815359"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50815356"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anti-inhibitor Coagulant Complex (Human): Emicizumab may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53545799"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should use effective contraception during therapy.</p></div>
<div class="block pri drugH1Div" id="F50848412"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted.</p>
<p style="text-indent:0em;margin-top:2em;">Emicizumab is a humanized monoclonal antibody (IgG<sub>4</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Therapies other than emicizumab are currently recommended for the management of hemophilia A in pregnant patients (WFH [Srivastava 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53571439"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor for thrombotic microangiopathy and thrombotic events if activated prothrombin complex concentrate is administered with emicizumab.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor coagulation parameters using single factor assays utilizing chromogenic or immuno-based methods; due to the long half-life of emicizumab, effects on coagulation assays may persist ≤6 months after the last dose. Chromogenic FVIII activity tests may be manufactured with either human or bovine coagulation proteins; human coagulation factors assays may overestimate the clinical hemostatic potential of emicizumab; however, bovine coagulation factors assays are insensitive to emicizumab (no activity measured) and can be used to monitor endogenous or infused FVIII activity, or to measure anti-FVIII inhibitors. Emicizumab will produce a false negative result in clotting-based Bethesda assays for functional inhibition of FVIII; a chromogenic Bethesda assay utilizing a bovine-based FVIII chromogenic test that is insensitive to emicizumab may be used.</p></div>
<div class="block pha drugH1Div" id="F50848418"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Emicizumab, a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific factor IXa- and factor X-directed antibody, bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis. Emicizumab has no structural relationship or sequence homology to FVIII and, therefore, does not induce or enhance the development of direct inhibitors to FVIII.</p></div>
<div class="block phk drugH1Div" id="F50848419"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic parameters were not influenced by age and similar in pediatric and adult patients (1 to 77 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 10.4 L</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: 80.4% to 93.1%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 26.9 ± 9.1 days</p></div>
<div class="block phksp drugH1Div" id="F51154033"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Clearance and volume of distribution increase with increasing body weight (9 kg to 156 kg). Dosing in mg/kg provides similar emicizumab exposure across body weight range.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F51377753"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hemcibra</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Gemlibra</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Hemlibra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Hemlibra.1">
<a name="Hemlibra.1"></a>Hemlibra (emicizumab-kxwh) [prescribing information]. South San Francisco, CA: Genentech Inc; March 2023.</div>
</li>
<li>
<div class="reference">
                  Hemlibra (emicizumab-kxwh) [prescribing information]. South San Francisco, CA: Genentech Inc; June 2022.</div>
</li>
<li>
<div class="reference">
                  Hemlibra (emicizumab) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30157389">
<a name="30157389"></a>Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. <i>N Engl J Med</i>. 2018;379(9):811-822. doi: 10.1056/NEJMoa1803550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emicizumab-pediatric-drug-information/abstract-text/30157389/pubmed" id="30157389" target="_blank">30157389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emicizumab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emicizumab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emicizumab-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 119618 Version 63.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
